Latest close: a new 52-week highSep 8, 2026what changed →5/10Strongest Momentum, weakest Quality · ranked vs Healthcare peers. The five questions below judge the company on its own terms.
Price
$37.83+71%1Y
1M+10%1Y+71%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageValue67
Quality7
Momentum70
Growth-
What they do
Pharvaris is a late-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases.
In the company’s own words · 20-F filed Apr 2, 2026 · SEC EDGAR
P/E (TTM)-
Market Cap$2.33B
1Y Return+71%
5Y Return+129%
Raw charts
2 series · TTMAs reported to the SEC, without any scoring.